Another historic day! Proud to announce a 5th #COVID19 vaccine candidate funded by #NIH & @BARDA began enrollment for its Phase 3 clinical trial. NVX-CoV2373, developed by @Novavax, will enroll up to 30k volunteers from U.S./Mexico. https://t.co/K9w2dxFmww

— Francis S. Collins (@NIHDirector) December 28, 2020

News: Phase 3 trial of Novavax investigational COVID-19 vaccine opens https://t.co/ApJW4gcfeF

— NIH (@NIH) December 28, 2020

The @Novavax #COVID19 vaccine candidate, NVX-CoV2373, uses a stabilized form of the coronavirus spike protein which cannot replicate to induce an immune response. It's administered in liquid form and can be stored/handled/distributed at a 35-46°F. https://t.co/ftL3gNxXzG pic.twitter.com/2ixvm0Z74j

— NIH (@NIH) December 28, 2020

Read more from @NIH ⬇️ https://t.co/wjlA4DQfZv

— Secretary Alex Azar (@SecAzar) December 28, 2020

.@Novavax launched a Phase 3 #clinicaltrial for #COVID19 vaccine candidate NVX-CoV2373 funded by @NIH & @BARDA. The investigational vaccine uses a stabilized form of the coronavirus spike protein (which cannot replicate) to induce an immune response. https://t.co/X3s0rx8C5a pic.twitter.com/gqWwQcWHhO

— HHS.gov (@HHSGov) December 28, 2020

The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at 115 sites in the United States and Mexico. https://t.co/OdDg2sWSRw

— C. Michael Gibson MD (@CMichaelGibson) December 28, 2020

We have another Phase III coronavirus vaccine trial here in the US, this one for Novavax’s vaccine candidate.

The trial is looking to recruit 30,000 people in the US. If you’re interested, click the link at the bottom of this article :) https://t.co/xT8QWYqEkm

— Alicia Smith (@Alicia_Smith19) December 29, 2020